Summary Report 2012 - Boehringer Ingelheim

Value through Innovation
Summary Report 2012

BOEHRINGER INGELHEIM
GROUP OF COMPANIES
Amounts in millions of EUR,
unless otherwise indicated 2012 2011 Change
Net sales 14,691 13,171 12%
by region
Europe 29% 31%
Americas 47% 46%
Asia, Australasia, Africa 24% 23%
by business
Human Pharmaceuticals 93% 93%
Animal Health 7% 7%
Research and development 2,795 2,516 11%
Personnel costs 4,024 3,664 10%
Average number of employees 46,228 44,094 5%
Operating income 1,853 2,272 — 18%
Operating income as % of net sales 12.6% 17.3%
Income after taxes 1,237 1,476 — 16%
Income after taxes as % of net sales 8.4% 11.2%
Shareholders’ equity 6,178 7,466 — 17%
Return on shareholders’ equity 16.6% 22.8%
Cash flow 2,225 2,378 — 6%
Investments in tangible assets 562 458 23%
Depreciation of tangible assets 793 535 48%
2
Boehringer Ingelheim summary report 2012

usiness year 2012
financial highlights
OUR COMPANY
Boehringer Ingelheim is a research-driven
company dedicated to researching and
developing, manufacturing and marketing
pharmaceuticals that improve health and
quality of life.
Our business areas consist of Human Pharma -
ceuticals and Animal Health. We have more
than 46,000 employees in 140 affi liated companies
worldwide, research and development
(R&D) facilities at six sites worldwide and
20 production plants in 13 countries. R&D
expenditure in Prescription Medicines corresponds
to 22.5% of its net sales.
Our headquarters is at Ingelheim, the German
town where the family-owned company was
founded in 1885.
Financial Highlights 3

KEY ASPECTS 2012
andreas barner, wolfram carius, allan hillgrove,
joachim hasenmaier, hubertus von baumbach
(from left to right), the board of managing directors
Dear readers,
Successful long-term, sustainable development of the company,
allied with stable earnings and sound finances, is and
will remain the basis of our independence and is central to
the strategic direction of the Boehringer Ingelheim group of
companies. Besides independence, the paramount goal is our
most important endeavour to make in equal measure available
a high level of medical progress to patients and physicians
treating them by researching innovative medicines, especially
in indications with urgent medical need.
Growth maintained
In 2012, Boehringer Ingelheim was able to build on its successful,
above-market growth from the previous year and
achieved a growth rate of + 11.5%.
4
Boehringer Ingelheim summary report 2012

usiness year 2012
key aspects 2012
Both our new products, such as the anticoagulant pradaxa®
and the diabetes medication trajenta®, as well as established
products, such as the respiratory medicines spiriva® and
combivent®, were the main growth drivers – all of these
products from our own research.
Stable earnings and financial position in a difficult market
Boehringer Ingelheim made an operating profit of EUR
1,853 million. This corresponds to an operating margin
of 12.6%.
We are satisfied with this result, as the successful operative
business development overall was negatively impacted by a
multitude of one-off and extraordinary effects. These effects are
the result of decisions which we have taken in order to prepare
the group of companies for a changing business environment.
Our financial management aims to ensure liquidity, limit
financial risks and optimise the cost of capital. It is noteworthy
that it allows the overall financing of the group of
companies to maintain our independent, organic growth.
Outlook
We are convinced, on the basis of our established product
portfolio and the successful launches of new products from
our own research and development expected for 2013 and
beyond will sustainably reinforce and expand our position in
the global human and veterinary pharmaceuticals market.
For 2013, we expect to be able to maintain growth and anticipate
a mid-single digit increase in sales compared to the
fi nancial year 2012.
Key aspects 2012
5

PERSPECTIVES FOR
MEDICAL INNOVATION
Boehringer Ingelheim’s commitment to emerging science as a
basis for new medicines grows ever stronger. As such, we focus
on studying human disease, the subsets of each disease and
establishing target-disease relationships that enable us to ask
the right questions.
Our aim is to help patients by treating diseases in areas of
high unmet medical need both in our current therapeutic area
focus and in new emerging disease areas. Our R&D activities
include both small molecules and biotherapeutics, thereby
allowing us to choose the most appropriate approach for each
therapeutic concept.
RESEARCH AREAS
[ in focus: six major areas ]
respiratory
diseases
cardiometabolic
diseases
oncology
central nervous
system diseases
immunology
infectious
diseases
6
Boehringer Ingelheim summary report 2012

perspectives
for medical innovation
OUR RESEARCH AND DEVELOPMENT SITES
[ 3 major and 3 specialised sites ]
2
1
3
4
5
6
1 ridgefield, usa
2 laval, canada
3 biberach and
ingelheim, germany
4 vienna, austria
5 milan, italy
6 kobe, japan
Status 31.12.2012
THE BOEHRINGER INGELHEIM PIPELINE
[ compounds in development, total 94 ]
17
respiratory
diseases
9
immunology
10
cns diseases
3
infectious
diseases
24
oncology
31
cardiometabolic
diseases
Research & development
7

RESEARCH WITH PASSION
In 2012, we employed an average of 7,492 people at our R&D
sites. A total of almost EUR 2.8 billion was invested in the research
and development of new medicines. R&D expenditure
in the business area Prescription Medicines corresponds to
+ 22.5% of its net sales.
Human Pharmaceuticals
In Human Pharmaceuticals we are presented with a wellfilled
pipeline of competitive substances, mainly in oncology,
diabetes, asthma and hepatitis C. We also have a tightly scheduled
series of planned launches of product innovations and
thereby continued growth potential.
After entering the diabetes market in 2011, we expect to enter
the oncology market in 2013 and extend our respiratory portfolio.
The substances from the advanced pipeline, foremost
afatinib in lung cancer and tiotropium or olodaterol in respiratory
diseases, have the potential to be ready for the market
as early as in 2013 as well as in the next few years.
8
Boehringer Ingelheim summary report 2012

perspectives
for medical innovation
Our R&D activities include both small molecules
and biotherapeutics, thereby allowing
us to choose the most appropriate approach
for each therapeutic concept.
Animal Health
In Animal Health the focus is on the research and development
of innovative vaccines, primarily for protecting livestock and
companion animals, as well as on pharmaceutical products.
Boehringer Ingelheim invested around EUR 115 million in 2012,
roughly 11% of total Animal Health sales, in researching and
developing new products and in building up a global network
of new R&D sites. An average 450 employees worked at Animal
Health’s R&D sites in the USA, Germany, Mexico, China and
Japan in 2012.
Further information:
annualreport.boehringer-ingelheim.com
Research & development
9

OUR BUSINESS AREAS
Boehringer Ingelheim divides its business activities into
the areas Human Pharmaceuticals, Biopharmaceuticals and
Animal Health.
Human Pharmaceuticals
The sales of our Human Pharmaceuticals business were
EUR 13,080 million, thereby showing gratifying growth
of around + 12%.
Prescription Medicines
The business area Prescription Medicines generated sales
growth of + 13%, amounting to EUR 11,405 million. In 2012,
our anticoagulant pradaxa®, with sales of EUR 1.1 billion,
exceeded the EUR 1 billion sales mark for the first time.
The products spiriva® (EUR 3.6 billion), already established
for 10 years, micardis® (EUR 1.6 billion) and combivent®
(EUR 883 million) continued to record growth in sales.
In addition, trajenta®, for the treatment of type 2 diabetes,
has significant sales potential. We consider it very disappointing
that trajenta®, a medication developed and manufactured in
Germany, is precisely not available in Germany for patients
with type 2 diabetes. We remain convinced that trajenta®
[ spiriva® ]
[ micardis® ]
10
Boehringer Ingelheim summary report 2012

kapitelname
perspectives
kapitelname
for better health
has a distinct, patient-relevant, added benefit and we consider
our position confirmed by positive therapeutic experiences in
some 40 countries around the world.
Consumer Health Care
The business area Consumer Health Care expanded again,
mainly in emerging markets and achieved worldwide sales
of EUR 1,505 million, corresponding to growth of + 7.8%
compared to the previous year.
Biopharmaceuticals
The business area Biopharmaceuticals focuses on the development
and production of new, innovative biopharmaceuticals.
It is comprised of the contract manufacturing business,
biosimilars and the research and development of new biological
active ingredients. Here, Boehringer Ingelheim achieved
net sales amounting to EUR 549 million (+ 5.8%).
Animal Health
The products in our Animal Health business developed
equally favourably, with total sales of EUR 1,062 million
(+ 8.8%) led by ingelvac circoflex®, a swine vaccine, with
sales of EUR 279 million (+ 8.6%).
[ pradaxa® ] [ ingelvac circoflex® ]
Our businesses
11

BOEHRINGER INGELHEIM
CORPORATION
Net sales by businesses
(in millions of EUR) 2012 2011 Change
Prescription Medicines 11,405 10,096 13.0%
Consumer Health Care 1,505 1,396 7.8%
Pharma Chemicals and
Pharmaceuticals Production 162 178 — 9.0%
Biopharmaceuticals 549 519 5.8%
Animal Health 1,062 976 8.8%
Net sales by region (in millions of EUR) 2012 2011 Change
Americas 6,905 6,087 13.4%
Europe 4,194 4,037 3.9%
Asia, Australasia, Africa (AAA) 3,592 3,047 17.9%
Key figures (in millions of EUR) 2012 2011 Change
Net sales 14,691 13,171 11.5%
Operating income 1,853 2,272 — 18.4%
Return on net sales 12.6% 17.3%
RESEARCH AND DEVELOPMENT
R&D Key figures 2012 2011 2010 2009 2008
Expenditure in millions of EUR 2,795 2,516 2,453 2,215 2,109
– as % of net sales 19.0 19.1 19.5 17.4 18.2
Prescription Medicines
expenditure in millions
of EUR 2,563 2,372 2,306 2,100 2,016
– as % of Prescription
Medicines net sales 22.5 23.5 23.8 20.9 22.1
Average number of employees 7,492 7,159 7,093 6,934 6,788
Investments in tangible assets
(without investments in infrastructure)
in millions of EUR 139 112 83 125 145
12
Boehringer Ingelheim summary report 2012

usiness year 2012
at a glance
PRESCRIPTION MEDICINES
Net sales (in millions of EUR) 2012 2011 Change
spiriva® 3,562 3,153 13.0%
micardis® 1,623 1,593 1.9%
pradaxa® 1,108 629 76.2%
combivent® 883 766 15.3%
CONSUMER HEALTH CARE
Net sales (in millions of EUR) 2012 2011 Change
buscopan® 212 180 17.8%
dulcolax® 193 171 12.9%
mucosolvan® 166 160 3.8%
pharmaton® 136 137 — 0.7%
ANIMAL HEALTH
Net sales (in millions of EUR) 2012 2011 Change
ingelvac circoflex® 279 257 8.6%
metacam® 99 96 3.1%
ingelvac® prrs 68 57 19.3%
vetmedin® 49 46 6.5%
EMPLOYEES
Average number of employees
by region 2012 2011
Americas 15,208 14,300
Europe 22,106 21,380
Asia, Australasia, Africa (AAA) 8,914 8,414
46,228 44,094
At a glance
13

CORPORATE BODIES
Shareholders’ Committee
christian boehringer
Chairman of the Shareholders’ Committee
christoph boehringer
erich von baumbach jr.
ferdinand von baumbach
isabel boehringer
dr mathias boehringer
Advisory Board
prof. dr michael hoffmann-becking
Attorney at Law, Düsseldorf, Chairman of the Advisory Board
egbert appel
Trustee, Martin Hilti Family Trust
Member of the Board and Managing Director, Hilti Foundation
dr andreas kreimeyer
Member of the Board of Executive Directors and
Research Executive Director, BASF SE
prof. dr fredmund malik (until 31.12.2012)
Chairman of the Board, Malik Management Zentrum St. Gallen AG
jan rinnert
Vice Chairman of the Board of Management, Heraeus Holding GmbH
Board of Managing Directors*
prof.** dr dr andreas barner
Chairman of the Board, Corporate Board Divisions Human Resources and
Research, Development and Medicine
hubertus von baumbach
Corporate Board Division Finance
prof. h.c. dr wolfram carius
Corporate Board Divisions Biopharmaceuticals and Operations
dr joachim hasenmaier (from 01.10.2012)
Corporate Board Divisions Animal Health and Consumer Health Care
allan hillgrove (from 01.01.2013)
Corporate Board Division Pharma Marketing and Sales
engelbert tjeenk willink (until 31.12.2012)
Corporate Board Division Pharma Marketing and Sales
* Change of structure of Corporate Board Divisions from 01.10.2012
** Republic of Austria
14
Boehringer Ingelheim summary report 2012

corporate bodies
imprint
If you have any queries or comments,
please contact us.
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim
Germany
Telephone + 49 6132 77-0
Fax + 49 6132 72-3000
Contact
Corporate Division Communications
E-mail webmaster@boehringer-ingelheim.com
Internet www.boehringer-ingelheim.com
Issued by
Boehringer Ingelheim GmbH
Design and layout
mpm · Corporate Communication Solutions
www.digitalagentur-mpm.de
Printed by
Süddeutsche Verlagsgesellschaft, Ulm
Copyright
©
Boehringer Ingelheim GmbH, 2013
All rights reserved. No part of this Annual Report 2012 may be reproduced
or transmitted in any form or by any means, electronic or photocopy,
without permission in writing from Boehringer Ingelheim GmbH.
Figures from third parties used in the annual report are based on data
available at the time the financial statement was drawn up.
With the CO 2
emission reduction certificates we support a project that distributes water
treatment units to households in rural districts in Kenya. The project improves public
health significantly, inasmuch as it guarantees access to clean drinking water.
Imprint
15

www.boehringer-ingelheim.com
annualreport.boehringer-ingelheim.com